secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cyclerion Therapeutics, Inc. (CYCN)
CIK:        0001755237
Form:       8-K
Filed at:   2022-07-28T23:59:59+00:00
Accession:  0000950170-22-013289
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cyclerion CY6463 shows cognition effect size 0.60 in CIAS study; well tolerated
-------------------------------------------------------------------------------

- Effect size 0.60 on Cogstate Schizophrenia Battery composite after 14 days of 15 mg CY6463 vs placebo.
- No SAEs, severe AEs, or discontinuations due to AEs; all adverse events transient.
- Favorable changes observed in broad panel of plasma inflammatory biomarkers linked to schizophrenia.
- 48 adults with stable schizophrenia on single atypical antipsychotic; PK linear dose-proportional.
- Company exploring partnerships; webinar July 28 at 8:00 a.m. EDT to discuss data.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1755237/000095017022013289/0000950170-22-013289-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1755237/000095017022013289/cycn-20220728.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-013289

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer